Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ribose (Furanose). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL23610533 | 0.88 | F7 (0.54) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL17315036 | 0.88 | F7 (0.54) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL28731657 | 0.86 | F7 (0.51) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL14321532 | 0.86 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL338518 | 0.86 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL18185139 | 0.86 | F7 (0.59) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL23111913 | 0.85 | F7 (0.58) | F7F3SARM1SIRT2SIRT6 | |
| Ribose (Furanose) SCHEMBL17315074 | 0.84 | F7 (0.56) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL17315895 | 0.83 | EGFR (0.42) | EGFRPTGS2F7F3SARM1 | |
| Ribose (Furanose) SCHEMBL28731396 | 0.83 | F7 (0.48) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059727-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | BIOSYNTH AG (CH) | 2024-02-22 | — | — | US | claimed |
| EP-4281465-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | Biosynth AG (CH) | 2023-11-29 | — | — | EP | claimed |
| US-20240059727-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | BIOSYNTH AG (CH) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059727-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS BY SALT METATHESIS, THE CRYSTALLINE FORM OF ITS TOSYLATE SALT AND THE CO-CRYSTALLIZED FORM OF ITS CHLORIDE:IODIDE SALT | NNMT, NAMPT, COASY | EGFR 4293/4885PTGS2 3621/4885F7 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.